Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Figure S1A Figures S1A & S1B: Forest plots showing hazard ratio (HR) for overall survival (OS; A) and progression-free survival (PFS; B) comparing subgroups of left-sided and rightsided colorectal cancer. Effect of PTL on outcome is considered for each treatment arm of the studies. Caption: n = number of patients; CI = confidence interval; PTL = primary tumour location; RC = right-sided colorectal cancer; LC = left-sided colorectal cancer; FE = fixed-effect model; RE = random-effect model; Cap = capecitabine; FOL = folinic acid; F = fluorouracil; L = leucovorin; I(RI) = irinotecan; OX = oxaliplatin; bev = bevacizumab; cet = cetuximab Figure S1B Figure S2A Figures S2A and S2B: Results of univariate meta-regressions for overall survival (OS; A) and progression-free survival (PFS; B). Caption: Left-sided colorectal cancer is taken as reference. HR = hazard ratio; CI = confidence interval; bev = bevacizumab; cet = cetuximab; chemo, chemotherapy Figure S2B Figure S3A Figures S3A & S3B: Funnel plots of logarithmic hazard ratio for overall survival (OS; A) and progression-free survival (PFS; B) drawn from the random-effects model of the meta-analysis in Fig. 1. Caption: Each study is represented by one dot; the vertical line represents the pooled effect estimate. OS = overall survival; PFS = progression-free survival; HR = hazard ratio Figure S3B Figure S4 Figure S4: Interaction test between primary tumour location (PTL) and treatment benefit from anti-EGFR antibody. Displayed are the results of univariate meta-regressions for overall survival (OS), progression-free survival (PFS) and overall response rate (ORR) when tumour side is used as predictor. Comparison of hazard ratio (HR) and odds ratio (OR) according to PTL is displayed. Figure S5 Figure S5: Interaction test between primary tumour location (PTL) and treatment effects of anti-EGFR or anti-VEGF-based treatment. Displayed are the results of univariate meta-regressions for overall survival (OS), progression-free survival (PFS) and overall response rate (ORR) when tumour side is used as predictor. Comparison of hazard ratio (HR) and odds ratio (OR) according to PTL is displayed.